Celebrating the new era of oncology
The annual ESMO Congress returns to be an onsite event after two years of COVID-19 pandemic, offering attendees opportunities to share knowledge on how to integrate molecular and digital tools into oncology
Gender equity in oncology – are we nearer to close the gender gap?
At the ESMO Women for Oncology Forum, international experts will discuss the latest data on female representation in the field
Practice-changing treatments in GU cancers continue to evolve
Finding the best treatment strategy for patient subpopulations and adequate funding are key to further advancing the field, says ESMO Award 2022 recipient Prof. Karim Fizazi
AI and machine learning may change the course of translational research
However, according to the winner of the ESMO Award for Translational Research 2022, Dr Samra Turajlic, results will only be achieved through a collaborative effort of the oncology community
More women in leadership roles are key to patient-centred medicine
According to this year’s ESMO Women for Oncology awardee Prof. Fatima Cardoso, steps forward in gender equality have been made, but progress is still slow
More needs to be done in renal cancer
Up to 90% of patients will die from metastatic disease and the search for biomarkers lags behind other tumour types, says ESMO Lifetime Achievement Award 2022 winner Prof. Bernard Escudier
Lenvatinib plus pembrolizumab delays the time to deterioration of quality of life
In advanced pre-treated endometrial cancer, patient-reported outcomes support efficacy benefits of the combination therapy
What is the state of play for molecular profiling in gynaecological malignancies?
Two studies investigate the value of molecular profiling in the management of ovarian and endometrial cancers
How to improve cervical cancer screening in low- or middle-income countries?
Data presented at the ESMO Gynaecological Cancers Congress 2022 confirm the vital role of national screening programmes and highlight the importance of local access
Is molecular profiling for gynaecological cancers worth the cost?
In this era of precision medicine, affordable profiling is essential